VAP-1
Vascular adhesion protein-1 (VAP-1); Semicarbazide-sensitive amine oxidase (SSAO); Amine oxidase copper-containing 3 (AOC3)
VAP-1 is a is a dual-function protein with adhesion properties and semicarbazide-sensitive monoamine oxidase (SSAO) activity. VAP-1 is involved in leukocyte-subtype-specific rolling under physiological shear. And VAP-1 catalyzes the oxidation of primary amines leading to the production of ammonium, formaldehyde, methylglyoxal, and hydrogen peroxide. Its catalytic activity can lead to cellular oxidative stress, which has been implicated in several pathologies (atherosclerosis, diabetes, and Alzheimer's disease).
All Product Categories
-
VAP-1 Related Products (9)
Related Products (9)
-
Vapaliximab
0 ImagesCat. No.: HY-P99526CAS No.: 336801-86-6Synonyms: 2D10Vapaliximab (2D10) is a monoclonal antibody against human VAP-1.
-
PXS-4681A
0 ImagesPXS-4681A is a potent, selective, irreversible and orally active semicarbazide-sensitive amine oxidase (SSAO; VAP-1) inhibitor with a Ki of 37 nM. PXS-4681A shows highly selectivity over related amine oxidases, ion channels, and seven-transmembrane domain receptors. PXS-4681A has anti-inflammatory effects.
-
SNT-8370
0 ImagesCat. No.: HY-173596SNT-8370 is an orally active inhibitor of VAP-1 (IC50: 10 nM) and myeloperoxidase (MPO) (IC50: 17 nM), with >100-1000 fold more potency for VAP-1 and MPO versus other mammalian (per)oxidases. SNT-8370 inhibits MPO-mediated LDL lipid peroxidation. SNT-8370 inhibits leukocyte infiltration in lung injury models of acute inflammation. SNT-8370 is an anti-inflammatory agent, and can be used for research of inflammatory disorders.
-
VAP-1-IN-2
0 ImagesCat. No.: HY-153506CAS No.: 1279026-89-9VAP-1-IN-2 is an orally active VAP-1 inhibitor with an IC50 value of 0.025 μM against human VAP-1 and 0.015 μM against rat VAP-1. VAP-1-IN-2 inhibits urinary protein excretion and the progression of proteinuria in diabetic rats. VAP-1-IN-2 inhibits VAP-1 activity in rats. VAP-1-IN-2 can be used in research related to diabetes and nephropathy.
-
SSAO inhibitor-2
0 ImagesCat. No.: HY-143721CAS No.: 2671028-06-9SSAO inhibitor-2 is a selective semicarbazide-sensitive amine oxidase (SSAO/VAP-1) inhibitor with an IC50 of < 10 nM. SSAO inhibitor-2 can be used for the research of inflammation diseases, diabetes and diabetes-related diseases, mental disorders, pain-related diseases, ischemic diseases, vascular diseases, ocular diseases, fibrosis, neuroinflammatory diseases, cancer, and tissue transplant rejection.
-
VAP-1-IN-3
0 ImagesCat. No.: HY-157530CAS No.: 3054227-79-8
-
SSAO/VAP-1 inhibitor 1
0 ImagesCat. No.: HY-142444CAS No.: 2647975-06-0SSAO/VAP-1 inhibitor 1 is a potent inhibitor of SSAO/VAP-1. SSAO/VAP-1 promotes the transfer of Glucose transport 4 (GLUT 4) from adipocytes to the cell membrane, thereby regulating glucose transport. In endothelial cells, SSAO/VAP-1 can mediate the adhesion and exudation of leukocytes and endothelial cells, and participate in inflammatory responses. SSAO/VAP-1 inhibitor 1 has the potential for the research of inflammation and/or inflammation-related disease or diabetes and/or diabetes-related disease (extracted from patent WO2021102774A1, compound E3).
-
PXS-4728A free base
0 ImagesCat. No.: HY-112726ACAS No.: 1478364-40-7Synonyms: BI-1467335 free basePXS-4728A free base is an orally active, selective VAP-1/SSAO inhibitor with an IC50 of 5 nM and a Ki of 175 nM. PXS-4728A free base inhibits the expression of MMP-9. It reduces cell rolling, adhesion and migration, decreases cell infiltration levels, pro-inflammatory cytokines, chemokines and collagen deposition, and improves pulmonary function. PXS-4728A free base reduces the formation and progression of atherosclerotic plaques, and decreases blood lipid and blood glucose levels as well as body weight gain. PXS-4728A free base can be used in research related to chronic obstructive pulmonary disease, cystic fibrosis, acute pulmonary inflammation, acute lung injury, bronchiolitis obliterans syndrome, rhinovirus-exacerbated asthma, sepsis, Klebsiella pneumoniae pulmonary infection and atherosclerosis.
